PharmaTher Holdings Ltd.
PHRM
CNSX
| 11/30/2024 | 08/31/2024 | 05/31/2024 | 02/29/2024 | 11/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -13.58% | -17.57% | -4.72% | 13.35% | -9.62% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -65.76% | -51.22% | -24.00% | -14.46% | -11.98% |
| Operating Income | 65.76% | 51.22% | 24.00% | 14.46% | 11.98% |
| Income Before Tax | 69.24% | 64.12% | 51.99% | 14.49% | 37.14% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 69.24% | 64.12% | 51.99% | 10.27% | 35.08% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 69.24% | 64.12% | 51.99% | 10.27% | 35.08% |
| EBIT | 65.76% | 51.22% | 24.00% | 14.46% | 11.98% |
| EBITDA | 65.75% | 51.21% | 23.99% | 14.45% | 11.98% |
| EPS Basic | 69.27% | 64.07% | 51.93% | 10.32% | 35.76% |
| Normalized Basic EPS | 65.40% | 50.00% | 22.39% | 15.79% | 15.60% |
| EPS Diluted | 69.27% | 64.07% | 51.93% | 10.32% | 35.76% |
| Normalized Diluted EPS | 65.40% | 50.00% | 22.39% | 15.79% | 15.60% |
| Average Basic Shares Outstanding | 0.26% | 0.16% | 0.07% | 0.02% | 0.44% |
| Average Diluted Shares Outstanding | 0.26% | 0.16% | 0.07% | 0.02% | 0.44% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |